What are the current guidelines for the evaluation and management of dyspepsia?

Management of Dyspepsia: Evidence-Based Guidelines

All patients under age 55-60 without alarm features should receive non-invasive Helicobacter pylori testing and eradication therapy if positive, followed by empirical proton pump inhibitor (PPI) therapy at the lowest effective dose if symptoms persist. 1

Initial Evaluation and Risk Stratification

Age-Based Endoscopy Thresholds

• Urgent endoscopy is warranted for patients ≥55 years with dyspepsia and weight loss, or those >40 years from high gastric cancer risk areas or with family history of gastro-esophageal cancer. 1

• Non-urgent endoscopy should be considered for patients ≥55 years with treatment-resistant dyspepsia, or those with raised platelet count, nausea, or vomiting. 1

• For patients ≥60 years presenting with abdominal pain and weight loss, urgent abdominal CT scanning is recommended to exclude pancreatic cancer. 1

• The 2017 ACG/CAG guidelines use age ≥60 as the endoscopy threshold, while the more recent 2022 British Society of Gastroenterology guidelines lower this to ≥55 years, reflecting evolving evidence on gastric cancer risk stratification. 2, 1

Essential Laboratory Testing

• Perform complete blood count in all patients ≥55 years with dyspepsia. 1

• Check coeliac serology in all patients with functional dyspepsia who have overlapping irritable bowel syndrome symptoms. 1

Distinguishing GERD from Dyspepsia

• Patients with predominant or frequent heartburn/acid regurgitation (>once weekly) should be managed as gastroesophageal reflux disease, not dyspepsia. 1

First-Line Treatment Algorithm

Step 1: H. pylori Test and Treat Strategy

• All patients without alarm features should undergo non-invasive H. pylori testing using either ¹³C-urea breath test or stool antigen test. 1

• All H. pylori-positive patients must receive eradication therapy, which is highly efficacious for functional dyspepsia (strong recommendation, high-quality evidence). 1

• Confirmation of successful eradication is only necessary in patients at increased risk for gastric cancer. 1

• In populations with H. pylori prevalence ≤10%, empirical PPI therapy becomes more cost-effective than test-and-treat, though the test-and-treat approach may prevent future gastric adenocarcinoma. 1

Step 2: Empirical Acid Suppression

• For H. pylori-negative patients or those with persistent symptoms after eradication, prescribe empirical PPI therapy for 4-8 weeks at the lowest dose that controls symptoms. 1

• PPIs demonstrate strong efficacy without dose-response relationship, making low-dose therapy appropriate and cost-effective. 1

• H2-receptor antagonists may be used as an alternative acid suppression option, though evidence is weaker than for PPIs (weak recommendation, low-quality evidence). 1

Step 3: Prokinetic Therapy

• Prokinetics should not be used as first-line treatment but may be considered for postprandial distress syndrome subtype patients who fail acid suppression. 3

• Tegaserod has moderate-quality evidence supporting efficacy, while acotiamide, itopride, and mosapride have low-quality evidence; many prokinetics are unavailable outside Asia and the USA. 1

Lifestyle Modifications

• All patients with functional dyspepsia should be advised to engage in regular aerobic exercise (strong recommendation). 1

• Advise patients to limit foods that trigger their specific symptoms, though evidence for formal dietary interventions including low-FODMAP diets remains insufficient. 1, 4

Second-Line Treatment for Refractory Symptoms

Neuromodulator Therapy

• Tricyclic antidepressants (TCAs) are the most effective second-line treatment for functional dyspepsia, with strong evidence supporting their use as gut-brain neuromodulators. 1

• Start amitriptyline at 10 mg once daily at bedtime and titrate slowly to a maximum of 30-50 mg daily based on symptom response. 1

• Provide careful explanation that TCAs are being used for pain modulation and gut-brain axis effects, not depression, and counsel patients about potential side effects (dry mouth, constipation, drowsiness). 1

• Mirtazapine may be particularly useful for patients with weight loss and food aversion. 3

• SSRIs lack sufficient evidence for routine recommendation in functional dyspepsia. 3

Alternative Second-Line Options

• Antipsychotics such as sulpiride (100 mg four times daily) or levosulpiride (25 mg three times daily) may be efficacious but require careful patient counseling about rationale and side effects. 1

Management of Severe or Refractory Functional Dyspepsia

Multidisciplinary Approach

• Involve a multidisciplinary support team including gastroenterology, dietetics, and mental health services for patients with severe or refractory symptoms. 1

• Refer patients to specialized functional dyspepsia clinics with access to interested clinicians, dietetic support, efficacious drugs, and gut-brain behavioral therapies. 1

Critical Safety Considerations

• Avoid opioids and surgery in severe or refractory functional dyspepsia to minimize iatrogenic harm (strong recommendation). 1

• Screen patients presenting with weight loss and food restriction for eating disorders including avoidant restrictive food intake disorder (ARFID). 1

• Ensure early dietitian involvement to prevent overly restrictive diets that can worsen nutritional status. 1

Psychological Interventions

• Cognitive behavioral therapy should be offered to patients who do not respond to medical therapies. 3

• Establishing an empathic doctor-patient relationship with shared understanding of functional dyspepsia as a disorder of gut-brain interaction reduces healthcare utilization and improves quality of life. 1

Testing NOT Recommended

• Do not routinely perform gastric emptying studies or 24-hour pH monitoring in patients with typical functional dyspepsia symptoms. 1

• Routine abdominal ultrasound and motility studies are not recommended for standard functional dyspepsia evaluation. 3

Key Clinical Pitfalls to Avoid

• Do not assume alarm symptoms in patients <55-60 years automatically require endoscopy; consider severity and number of alarm features on a case-by-case basis. 1

• Recognize that most patients undergoing endoscopy for dyspepsia will have functional dyspepsia (>50%), not organic disease like peptic ulcer (approximately 10%). 1

• Avoid prescribing higher PPI doses for non-responders, as there is no dose-response relationship; instead, advance to neuromodulator therapy. 1

• Remember that functional dyspepsia has favorable long-term prognosis and life expectancy, though it significantly impacts quality of life. 5

• Patients responding to initial therapy can be managed long-term without endoscopy, as the probability of finding relevant organic disease in young patients without alarm features is very low. 1